Deep dive #2 · 31 October 2026

Coeliac disease

For health professionals

About 1 in 100 people have it and most don't know. The diet is the only treatment, about 4 in 10 adults still have villous atrophy on it, and the drug pipeline is a graveyard with one or two survivors. The numbers, the trials, and the gaps.

At a glance

Biggest take-home: test anyone with unexplained iron deficiency, type 1 diabetes, autoimmune thyroid disease or a first-degree relative with coeliac disease, and do it before they cut out gluten.

Definition

History

Pathophysiology

Genetics

Immune cascade

Glutengliadin peptides (e.g. the 33-mer) resist digestionTG2 deamidates themglutamine → glutamate: tighter HLA bindingPresented by HLA-DQ2 or DQ8necessary, not sufficientGluten-specific CD4⁺ T cellsB cellsanti-TG2 and anti-DGPantibodiesIL-15 licensesCD8⁺ intraepitheliallymphocytesSerology targetstTG-IgA, DGP-IgGVillous atrophycrypt hyperplasia (Marsh)
From gluten to the blood test and the flat biopsy (simplified). Download this diagram

Infant feeding: timing doesn't prevent it

Epidemiology

Global

Australia

Causes and risk factors

Preventable factors

Diagnosis essentials

Current treatment

Lifelong gluten-free diet

Follow-up

Non-responsive and refractory disease

Dermatitis herpetiformis

Emerging treatments and trials

No drug is approved anywhere. FDA guidance on drugs as an add-on to the GFD is still a draft (2022).

Still standing

Fallen

Theoretical frontiers

Hypotheses, not recommendations.

Causes: theories

Prevention: theoretical options

Treatment: theoretical options

Gaps and open questions

Labelled hypotheses, not recommendations.

Prognosis and quality of life

Weird trivia

Guidelines

Key trials

Sources

Information only. Test choice, gluten challenge amounts and biopsy rules differ between guidelines and labs. Check local pathways and current guidance before acting.

Updated 31 October 2026. General education for health professionals; not a substitute for local protocols.